Page 25 - Cipla

Cipla hits 52-week low on disappointing Q4 results

The stock dipped 7% to Rs 460, also its 52-week low on the BSE.

Cipla net profit declines 69% due to one-off expenses

Cipla's Ebitda also declined nearly 57% to Rs 219 crore

Cipla Q4 net drops 69% to Rs 81 cr

Consolidated total income from operations of the company stood at Rs 3,266.54 crore for the quarter under consideration

Cipla bets big on consumer health segment

Company aims to build five Rs 100 cr-plus brands and launch products from South African arm in domestic market

Cipla invests additional $ 3 million in US's Chase Pharmaceuticals

Company in May 2014 had invested $1.5 million to acquire 14.6% stake in Chase Pharmaceuticals

Cipla transfers consumer healthcare business to subsidiary

Shares of Cipla today closed at Rs 517.50 per scrip on BSE, up 0.49% from the previous close

Cipla completes $550 million acquisition of 2 US generic drug companies

The acquisition of InvaGen and Exelan will boost Cipla's US business which currently accounts for 8% of its revenue